We are happy to announce that Mattias Ohrlander has joined Biomedical Bonding AB as our new Chief Operating Officer, effective May 15th, 2024. This strategic addition to our team marks an exciting step forward in our journey towards innovative medical solutions.
With over 25 years of invaluable experience in the Medtech industry, Mr. Ohrlander brings a wealth of knowledge and expertise to Biomedical Bonding AB. His extensive background includes founding two Life Science business development companies and successfully participating in developing and commercializing several medical device products. His deep understanding of product and business development, standards, and regulatory compliance for medical devices will ensure that our products meet the highest levels of safety and efficacy, making them well-suited as alternative solutions for existing metal fixators of fractures. As we move forward, Mr. Ohrlander's guidance will be instrumental in navigating Biomedical Bonding AB towards the establishment of its quality management system and ISO 13485 accreditation.
Professor Michael Malkoch, Founder of Biomedical Bonding AB, expresses his enthusiasm for Mr. Ohrlander's appointment, stating, "I am happy to have Mr. Ohrlander onboard as the COO for Biomedical Bonding AB. As part of the management, his contribution will be of great value as the company intends to steer its first product towards First-in-Human clinical trials."
We are excited about the possibilities ahead with Mr. Ohrlander on board and look forward to achieving new milestones together. Join us in welcoming him to the Biomedical Bonding AB team as we continue to lead the way in orthopedic innovation.
Comments